Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisinopril + carvedilol + spironolactone + losartan + digoxin
- Development stage
- Phase 4
- Lead developer
- University of Louisville
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The RESTAGE-HF pharmacological regimen is an aggressive combination therapy developed by the University of Louisville for patients with advanced (Stage D) non-ischemic heart failure. Used in conjunction with mechanical unloading via a Left Ventricular Assist Device (LVAD), this protocol aims to induce myocardial recovery and heart failure remission. The regimen consists of standardized, high-dose titration of five existing medications: lisinopril (an ACE inhibitor), carvedilol (a beta-blocker), spironolactone (a mineralocorticoid receptor antagonist), losartan (an angiotensin receptor blocker), and digoxin (a cardiac glycoside). By targeting multiple neurohormonal pathways, the treatment promotes reverse structural remodeling of the failing heart, potentially allowing for the eventual removal of the LVAD in a significant proportion of patients.
- Other names
- RESTAGE-HF pharmacological regimenRESTAGE-HF protocol
02
Targets
ADRA1A (α1A)AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)ADRB1 (β1)ADRB2 (β2)MR (Mineralocorticoid receptor)ATP1A (Sodium/potassium-transporting ATPase)
Beyond the preview
Go deeper on lisinopril + carvedilol + spironolactone + losartan + digoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisinopril + carvedilol + spironolactone + losartan + digoxin.